Literature DB >> 10174314

The impact of Parkinson's disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey.

L M Rubenstein1, E A Chrischilles, M D Voelker.   

Abstract

Parkinson's disease (PD) is a common disorder that leads to severe disability, despite pharmacological and surgical interventions. As PD progresses, patients and their families experience substantial health and economic burdens. Little research has been conducted into the economic consequences of PD or the impairment of health dimensions, such as social function and mental health, that may accompany the deterioration in economic resources and physical function. In the current study, the US National Medical Expenditure Survey (NMES) was examined as a source of population-based information about health-resource use, medical expenditures and health status. 43 patients with PD were identified, and each was matched with 3 individuals without PD to estimate the costs attributable to PD. Data from the NMES demonstrate the serious health and economic burdens of PD. The patients with PD were clearly shown to have decreased health status, increased health expenditures and lost productivity relative to controls. However, these estimates of the magnitude of disease burden must be used with caution. The small sample size appears to have inadequately represented patients in the earliest and the most advanced stages of PD. There was also considerable variability in case-control groups, resulting in wide confidence intervals for the estimates.

Entities:  

Mesh:

Year:  1997        PMID: 10174314     DOI: 10.2165/00019053-199712040-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  26 in total

1.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

Authors:  S KATZ; A B FORD; R W MOSKOWITZ; B A JACKSON; M W JAFFE
Journal:  JAMA       Date:  1963-09-21       Impact factor: 56.272

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

Review 3.  Clinical economics. A guide to the economic analysis of clinical practices.

Authors:  J M Eisenberg
Journal:  JAMA       Date:  1989-11-24       Impact factor: 56.272

4.  Social costs of Parkinson's disease.

Authors:  E Singer
Journal:  J Chronic Dis       Date:  1973-04

5.  Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39)

Authors:  C Jenkinson; V Peto; R Fitzpatrick; R Greenhall; N Hyman
Journal:  Age Ageing       Date:  1995-11       Impact factor: 10.668

6.  Quality of life in patients with Parkinson's disease: development of a questionnaire.

Authors:  A G de Boer; W Wijker; J D Speelman; J C de Haes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

Review 7.  [Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy].

Authors:  R C Dodel; S Pepperl; R Köhne-Volland; T Szucs; K J Werhahn; S Noachtar; W H Oertel
Journal:  Med Klin (Munich)       Date:  1996-07-15

8.  Projected neurodegenerative disease mortality in the United States, 1990-2040.

Authors:  D E Lilienfeld; D P Perl
Journal:  Neuroepidemiology       Date:  1993       Impact factor: 3.282

Review 9.  Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease.

Authors:  J A Saint-Cyr; A E Taylor; A E Lang
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

Review 10.  Epidemiology of Parkinson's disease.

Authors:  C M Tanner
Journal:  Neurol Clin       Date:  1992-05       Impact factor: 3.806

View more
  18 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

3.  Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.

Authors:  V Fraix; J-L Houeto; C Lagrange; C Le Pen; P Krystkowiak; D Guehl; C Ardouin; M-L Welter; F Maurel; L Defebvre; A Rougier; A-L Benabid; V Mesnage; M Ligier; S Blond; P Burbaud; B Bioulac; A Destée; P Cornu; P Pollak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

4.  Costs of illness in a Russian cohort of patients with Parkinson's disease.

Authors:  Yaroslav Winter; Sonja von Campenhausen; Georgy Popov; Jens P Reese; Jens Klotsche; Kai Bötzel; Eugene Gusev; Wolfgang H Oertel; Richard Dodel; Alla Guekht
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  Cost of illness and its predictors for Parkinson's disease in Germany.

Authors:  Annika E Spottke; Martin Reuter; Olaf Machat; Bernhard Bornschein; Sonja von Campenhausen; Karin Berger; Rudolf Koehne-Volland; Jürgen Rieke; Alexander Simonow; Dirk Brandstaedter; Uwe Siebert; Wolfgang H Oertel; Gudrun Ulm; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Health-related quality-of-life measurement in patients with Parkinson's disease.

Authors:  C Jenkinson; R Fitzpatrick; V Peto
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

7.  Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

Authors:  Cynthia S Palmer; Mark J C Nuijten; Jordana K Schmier; Prasun Subedi; Edward H Snyder
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Co-occurring chronic conditions and healthcare expenditures associated with Parkinson's disease: a propensity score matched analysis.

Authors:  Sandipan Bhattacharjee; Usha Sambamoorthi
Journal:  Parkinsonism Relat Disord       Date:  2013-05-13       Impact factor: 4.891

Review 9.  Cabergoline : a review of its use in the treatment of Parkinson's disease.

Authors:  Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.

Authors:  Michael Iskedjian; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.